Status:
UNKNOWN
Differential Mobility Spectrometry (DMS) Based Skin Tumor Analysis
Lead Sponsor:
Tampere University Hospital
Collaborating Sponsors:
Olfactomics Oy
Conditions:
Basal Cell Carcinoma
Eligibility:
All Genders
40-90 years
Brief Summary
The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by...
Detailed Description
Basal cell carcinoma (BCC) is the most common cancer in Caucasians and the average risk of developing BCC is approximately 30% (1,2). In Finland, BCC is the most common cancer and the incidence of BCC...
Eligibility Criteria
Inclusion
- Punch biopsy diagnosed basal cell carcinoma.
- Tumor diameter of 1,5 cm or larger.
- Operable patient that is willing to participate in the trial.
Exclusion
- Tumor diameter of less than 1,5 cm.
- Patient that is unsuitable to take part in the trial, for example, has a tendency to develop keloids.
- Patient that is unwilling to take part in the trial.
- Patient that is not able to understand given information concerning the trial or to give consent to take part in the trial.
Key Trial Info
Start Date :
December 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05247710
Start Date
December 9 2022
End Date
June 1 2024
Last Update
July 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampere University Hospital
Tampere, Finland